Skip to main content

Patricia Pozo Rosich

I am a doctor of medicine, specialist in neurology. I am head of the Neurology Service of Vall d'Hebron. I lead the Research Laboratory in Cephalea and Neurological Pain of the VHIR (Vall d’Hebron Research Institute) belonging to the Autonomous University of Barcelona (UAB).

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital
Patricia Pozo Rosich

Patricia Pozo Rosich

Patricia Pozo Rosich

Institutions of which they are part

Head of group
Headache and Neurological Pain
Vall Hebron Institut de Recerca
Neurology
General Hospital

I am a doctor of medicine, specialist in neurology. I am head of the Neurology Service of Vall d'Hebron. I lead the Research Laboratory in Cephalea and Neurological Pain of the VHIR (Vall d’Hebron Research Institute) belonging to the Autonomous University of Barcelona (UAB).

I am a member of the Executive Committee of the International Headache Society and the European Headache Federation and of the Committee for Clinical Trials of the International Headache Society. In addition, I am a member of the American Headache Society.

I specialized in the field of headache in the United States and London, in the laboratories of Professor Silberstein (Thomas Jefferson University) and Professor Goadsby (University of California at San Francisco and University College London – Queen Square), with the help of the “la Caixa” scholarships, AHS, EFNS, Rio Hortega, GECSEN.

My interest in the field of research focuses on better understanding the pathophysiology of migraine from a multidisciplinary approach using genetics, neuroimaging and electrophysiology. I have developed the Migraine Adaptive Brain research program that focuses on the neurosensory brain. I am a member of the International Consortium of Migration Genetics.

To carry out research projects I have received grants from the “la Caixa” Banking Foundation, the FIS (Health Research Fund) of the Carlos III Institute, the La MaratóTV3 Foundation, Migraine Research Foundation, MICINN (Ministry of Science and Innovation) and the Mutual Medical.

I am editor of the journals Frontiers in Neurology, Journal of Headache and Pain and director of the Cephalia Area of the Neurology Journal. I have published original articles in impact factor journals, review articles, book chapters, edited books and magazines and I am the author of books.

I also work in education. I am a clinical associate professor at the Autonomous University of Barcelona.

Projects

Cefalea i dolor neurològic

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez, Nara Ikumi Montserrat, Marta Vila Pueyo, Edoardo Caronna
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00406
Duration: 01/01/2022 - 30/06/2025

Fenotipado molecular de pacientes con migrañA según edad y Sexo a través de la cuanTificación de CGRP en saliva para realizar medicina de precisión: estudio FAST.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna, Laura Gómez Dabó
Funding agency: Instituto de Salud Carlos III
Funding: 81070
Reference: PI22/01501
Duration: 01/01/2023 - 31/12/2025

Biomarcadores neurofisiológicos en migraña

IP: Patricia Pozo Rosich
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 50649.27
Reference: VHIR/BEQUESPREDOC/2020/MARTI
Duration: 01/04/2021 - 30/03/2024

Cefaleas y síndromes post-traumatismo craneoencefálico

IP: Patricia Pozo Rosich
Collaborators: Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM20/00217
Duration: 01/01/2021 - 31/12/2022

Related news

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

Related professionals

Matteo Pusceddu

Matteo Pusceddu

Postdoctoral researcher
Physiology and Pathophysiology of the Digestive Tract
Read more
Mónica López Bardasco

Mónica López Bardasco

Administrative
Labour Relations Unit
Human Resources Directorate
Read more
Joan Rey Cano

Joan Rey Cano

Research technician
Systemic Diseases
Read more
Gemma Aran Canals

Gemma Aran Canals

Postdoctoral researcher
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.